Epizyme Inc. (NASDAQ:EPZM) CFO Andrew E. Singer sold 1,013 shares of the business’s stock in a transaction that occurred on Wednesday, November 9th. The shares were sold at an average price of $10.40, for a total value of $10,535.20. Following the completion of the sale, the chief financial officer now owns 30,613 shares of the company’s stock, valued at approximately $318,375.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Epizyme Inc. (NASDAQ:EPZM) opened at 11.75 on Tuesday. The firm’s market capitalization is $681.63 million. Epizyme Inc. has a 12 month low of $7.02 and a 12 month high of $18.29. The stock’s 50 day moving average price is $9.56 and its 200-day moving average price is $9.70.

Epizyme (NASDAQ:EPZM) last released its quarterly earnings data on Thursday, November 3rd. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.60) by $0.18. The business earned $6.60 million during the quarter. Epizyme had a negative net margin of 1,205.01% and a negative return on equity of 41.56%. Equities analysts forecast that Epizyme Inc. will post ($1.98) earnings per share for the current year.

Insider Buying and Selling by Quarter for Epizyme (NASDAQ:EPZM)

Several large investors have recently added to or reduced their stakes in EPZM. BlackRock Fund Advisors boosted its stake in Epizyme by 42.0% in the first quarter. BlackRock Fund Advisors now owns 1,698,516 shares of the biopharmaceutical company’s stock valued at $20,586,000 after buying an additional 502,627 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Epizyme by 550.8% in the first quarter. JPMorgan Chase & Co. now owns 153,656 shares of the biopharmaceutical company’s stock valued at $1,862,000 after buying an additional 130,044 shares in the last quarter. HBK Investments L P bought a new stake in shares of Epizyme during the first quarter valued at approximately $149,000. Candriam Luxembourg S.C.A. raised its stake in shares of Epizyme by 15.0% in the second quarter. Candriam Luxembourg S.C.A. now owns 184,000 shares of the biopharmaceutical company’s stock valued at $1,884,000 after buying an additional 24,000 shares in the last quarter. Finally, American Century Companies Inc. bought a new stake in shares of Epizyme during the second quarter valued at approximately $518,000. 80.89% of the stock is owned by institutional investors and hedge funds.

EPZM has been the subject of a number of research reports. Leerink Swann reiterated an “outperform” rating on shares of Epizyme in a report on Friday, October 7th. Wedbush restated an “outperform” rating and set a $22.00 target price on shares of Epizyme in a report on Friday, November 4th. Zacks Investment Research lowered Epizyme from a “buy” rating to a “hold” rating in a report on Wednesday, October 19th. HC Wainwright restated a “buy” rating on shares of Epizyme in a report on Tuesday, August 9th. Finally, JMP Securities restated a “buy” rating on shares of Epizyme in a report on Sunday, November 6th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $23.11.

About Epizyme

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s segment is the discovery and development of novel epigenetic therapies for cancer patients. It develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs.

5 Day Chart for NASDAQ:EPZM

Receive News & Stock Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related stocks with our FREE daily email newsletter.